Related Experiment Video

Updated: Jun 25, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current

George R Simon1

  • 1Thoracic Oncology Program for Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. george.simon@fccc.edu

Current Treatment Options in Oncology
|March 7, 2009
PubMed

Insights

Future cancer treatments will focus on molecular determinants to develop targeted therapies. Identifying these markers during drug development and in clinical trials will improve patient outcomes and survival rates.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Translational Medicine

Background:

  • The future of cancer treatment will increasingly involve therapies targeting specific molecular determinants.
  • Identifying these determinants is crucial for developing novel chemotherapeutic agents and enabling rational therapeutics.

Purpose of the Study:

  • To explore the future landscape of cancer treatment strategies centered on molecular determinants.
  • To highlight the importance of integrating molecular determinant identification into drug development and clinical trial design.

Main Methods:

  • This study is a conceptual exploration and future outlook, not based on empirical data.
  • It synthesizes current trends in precision medicine and therapeutic development.

Main Results:

  • Integrating molecular determinant identification with novel chemotherapeutic development is key.
  • Clinical trials enriching patients based on molecular determinants can improve response rates and survival.

Conclusions:

  • Patient-specific, individualized therapeutic cocktails based on molecular determinants hold promise for significantly improving treatment efficacy.
  • This approach represents a paradigm shift towards personalized oncology, enhancing patient outcomes.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...